Physician profile
Christopher M Prough
NPI 1194139121
$2,341.85
in general payments reported to CMS, 2019-2025
12 companies · $703 in 2025
The $703 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $120 · 2021: $150 · 2022: $102 · 2023: $282 · 2024: $882 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $404.33 | 2021-2024 | Total30 |
| Biotissue Holdings INC. | $303.41 | 2020-2024 | |
| Amgen INC. | $279.67 | 2024-2025 | Tepezza |
| Dompe US, INC. | $243.99 | 2024-2025 | Oxervate |
| Abbvie INC. | $241.71 | 2023-2024 | |
| Johnson & Johnson Vision Care, INC. | $225.12 | 2023-2025 | Acuvue |
| Glaukos Corporation | $193.27 | 2019-2024 | Ce-Marked Kxla System |
| Coopervision INC. | $154.46 | 2025 | Clariti Contact Lens, Biofinity Contact Lens |
| Harrow Eye, LLC | $121.93 | 2025 | Vevye |
| Optovue, INC. | $87.03 | 2019 | |
| Astellas Pharma US INC | $55.14 | 2024 | Izervay |
| Sight Sciences, INC. | $31.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Prough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.